{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:25:56Z","timestamp":1761920756330,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ajo.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T11:59:25Z","timestamp":1594814365000},"page":"332-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-6172","authenticated-orcid":false,"given":"Tanyatuth","family":"Padungkiatsagul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7528","authenticated-orcid":false,"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panitha","family":"Jindahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-447X","authenticated-orcid":false,"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2020.07.008_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial","volume":"115","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2020.07.008_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/WNO.0b013e31823a9ebc","article-title":"Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis","volume":"32","author":"Fernandes","year":"2012","journal-title":"J Neuroophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2020.07.008_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2020.07.008_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"12","key":"10.1016\/j.ajo.2020.07.008_bib5","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ajo.2020.07.008_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ajo.2020.07.008_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.07.008_bib8","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmun Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib9","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ajo.2020.07.008_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ajo.2020.07.008_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2013.7995","article-title":"Association of race\/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial","volume":"132","author":"Moss","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"22","key":"10.1016\/j.ajo.2020.07.008_bib14","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.ajo.2020.07.008_bib15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ajo.2020.07.008_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib17","doi-asserted-by":"crossref","first-page":"e007766","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.ajo.2020.07.008_bib18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458515614093","article-title":"The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients","volume":"22","author":"Siritho","year":"2016","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.ajo.2020.07.008_bib19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2020.07.008_bib21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2020.07.008_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.ajo.2020.07.008_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","article-title":"Poor prognosis of visual outcome after visual loss from giant cell arteritis","volume":"112","author":"Danesh-Meyer","year":"2005","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2020.07.008_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.ajo.2020.07.008_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ajo.2020.07.008_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.ajo.2020.07.008_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"6","key":"10.1016\/j.ajo.2020.07.008_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ajo.2020.07.008_bib29","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2020.07.008_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ajo.2020.07.008_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","article-title":"The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis","volume":"396","author":"Liu","year":"2019","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"1\u22122","key":"10.1016\/j.ajo.2020.07.008_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.ajo.2020.07.008_bib34","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1111\/aos.14013","article-title":"Simultaneous bilateral optic neuritis in China: clinical, serological and prognostic characteristics","volume":"97","author":"Kang","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2020.07.008_bib35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ejpain.2010.11.016","article-title":"Asians differ from non-Hispanic Whites in experimental pain sensitivity","volume":"15","author":"Rowell","year":"2011","journal-title":"Eur J Pain"},{"issue":"10","key":"10.1016\/j.ajo.2020.07.008_bib36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.ajo.2020.07.008_bib37","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2020.07.008_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13791","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes","volume":"26","author":"Zhou","year":"2019","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.ajo.2020.07.008_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMc052515","article-title":"Self-reported race\u00a0and genetic admixture","volume":"354","author":"Sinha","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2020.07.008_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1086\/427888","article-title":"Genetic structure, self-identified race\/ethnicity, and confounding in case-control association studies","volume":"76","author":"Tang","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.ajo.2020.07.008_bib41","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2105\/AJPH.88.9.1303","article-title":"European, Western, Caucasian, or what? Inappropriate labeling in research on race, ethnicity, and health","volume":"88","author":"Bhopal","year":"1998","journal-title":"Am J Public Health"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420303597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420303597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:44:23Z","timestamp":1757598263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939420303597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"alternative-id":["S0002939420303597"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2020.07.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"type":"print","value":"0002-9394"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}